Management of treatment-naïve LR-MDS

Program Description

Erythropoiesis-stimulating agents (ESAs) have been a mainstay of the first-line (1L) treatment of LR-MDS associated anemia; however, the recent expansion by the US Food and Drug Administration of the indication for luspatercept to include 1L therapy provides another option for community providers to consider. In this Phone-a-Friend activity, Drs. Andrew Kuykendall and Aditi Shastri discuss the recently published evidence related to 1L treatment options and provide their expert opinions regarding the best management approach for a patient with treatment-naïve LR-MDS and symptomatic anemia without the presence of ring sideroblasts.

Target Audience

The educational design of this activity addresses the needs of oncologists, hematologists, hematology-oncology fellows, as well as other allied health care professionals (HCPs) involved in the treatment of myelodysplastic syndrome (MDS).

Educational Objectives

After completing this activity, the participant should be better able to:

• Develop individualized treatment regimens based on patient- and disease-specific factors to reduce transfusion burden in LR-MDS and improve patient survival and quality of life outcomes

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Credit

The ANCC’s Commission on Accreditation recognizes educational activities that are approved for AMA PRA Category 1 Credits™ by providers who are accredited by the ACCME to award credit to learners. This reciprocity agreement allows nurses and nurse practitioners to use AMA PRA Category 1 Credits™ as approved ANCC contact hours for license renewal.

Disclosures of Relevant Financial Relationships

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Andrew Kuykendall, MD: Consulting Fees: AbbVie Inc., Blueprint Medicines Corporation, Bristol Myers Squibb Company, Celgene Corporation, CTI Biopharma Corporation, Geron Corporation, GSK plc, Imago Biosciences, Inc., Incyte Corporation, Karyopharm Therapeutics Inc., MorphoSys AG, PharmaEssentia Corporation, Silence Therapeutics plc; Contracted Research: Blueprint Medicines, Bristol Myers Squibb Company, Geron Corporation, GSK  plc, Janssen Pharmaceutical Companies, MorphoSys AG, Novartis AG, Protagonist Therapeutics Inc.

Aditi Shastri, MD: Consulting Fees: Kymera Therapeutics, Inc., Ryvu Therapeutics S.A.; Contracted Research: Kymera Therapeutics, Inc., Ryvu Therapeutics S.A.

The planners and managers at Integritas Communications have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas Communications does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 100% on the posttest and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Integritas Contact Information

For questions about this activity, please contact Integritas Communications at info@exchangecme.com.